Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL57126 | 1.00 | TDP1 (0.53) | TDP1L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL9021326 | 1.00 | TDP1 (0.53) | TDP1L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL9021214 | 1.00 | TDP1 (0.53) | TDP1L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL9021262 | 1.00 | TDP1 (0.53) | TDP1L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL9021124 | 1.00 | TDP1 (0.53) | TDP1L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL8500469 | 1.00 | TDP1 (0.53) | TDP1L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL8496728 | 1.00 | TDP1 (0.53) | TDP1L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL57993 | 1.00 | TDP1 (0.53) | TDP1L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL9022098 | 1.00 | TDP1 (0.53) | TDP1L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL8498166 | 1.00 | TDP1 (0.53) | TDP1L3MBTL1MEN1KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103420856-B | Salmeterol preparation method | ASYMCHEM LAB TIANJIN CO LTD | 2015-07-01 | — | — | CN | claimed |
| US-10588895-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2020-03-17 | — | — | US | disclosed |
| US-20190183867-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL SA (ES) | 2019-06-20 | — | — | US | disclosed |
| US-10034867-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2018-07-31 | — | — | US | disclosed |
| US-20170319557-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL PRODESFARMA, S.A. (ES) | 2017-11-09 | — | — | US | disclosed |
| US-9687478-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2017-06-27 | — | — | US | disclosed |
| US-RE46417-E1 | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands | ALMIRALL, S.A. (ES) | 2017-05-30 | — | — | US | disclosed |
| US-20160296503-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL PRODESFARMA, S.A. (ES) | 2016-10-13 | — | — | US | disclosed |
| US-9333195-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2016-05-10 | — | — | US | disclosed |
| US-20150246026-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL PRODESFARMA, S.A. (ES) | 2015-09-03 | — | — | US | disclosed |
| WO-2002053564-A2 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS M3 ANTAGONISTS | ALMIRALL PRODESFARMA AG (CH) | 2002-07-11 | — | — | WO | disclosed |
| WO-2002051841-A1 | QUINUCLIDINE CARBAMATE DERIVATIVES AND THEIR USE AS M3 ANTAGONISTS | ALMIRALL PRODESFARMA AG (CH) | 2002-07-04 | — | — | WO | disclosed |
| EP-1200431-A2 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR LIGANDS | Almirall Prodesfarma, S.A. (ES) | 2002-05-02 | — | — | EP | disclosed |
| EP-1094826-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ALPHA-1A ADRENERGIC RECEPTORS | Advanced Medicine, Inc. (US) | 2001-05-02 | — | — | EP | disclosed |
| WO-2001004118-A2 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR LIGANDS | ALMIRALL PRODESFARMA S.A. (ES) | 2001-01-18 | — | — | WO | disclosed |
| WO-1999064042-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ALPHA-1A ADRENERGIC RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| EP-0500853-B1 | PHENYLETHANOLAMINES, DRUGS CONTAINING THESE COMPOUNDS, AND A METHOD OF PREPARING THEM | THOMAE GMBH DR K (DE) | 1996-12-27 | — | — | EP | disclosed |
| US-5393774-A | Antispasmodic agents | PIEPER HELMUT (DE) | 1995-02-28 | — | — | US | disclosed |
| EP-0500853-A1 | PHENYLETHANOLAMINES, DRUGS CONTAINING THESE COMPOUNDS, AND A METHOD OF PREPARING THEM. | THOMAE GMBH DR K (DE) | 1992-09-02 | — | — | EP | disclosed |
| WO-1992004316-A1 | PHENYLETHANOLAMINES, DRUGS CONTAINING THESE COMPOUNDS, AND A METHOD OF PREPARING THEM | DR. KARL THOMAE GMBH (DE) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10034867-B2 | Quinuclidine derivatives and medicinal compositions containing the same | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHRM3, OPRD1 | TDP1 1697/4885L3MBTL1 4416/4885MEN1 3961/4885 |
| US-20160296503-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NQO2, CHRM3 | TDP1 1585/4885L3MBTL1 4150/4885MEN1 4078/4885 |
| US-20190183867-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | CHRM3, CHRNB1, ARRB1 | TDP1 2409/4885L3MBTL1 4238/4885MEN1 4586/4885 |
| US-20170319557-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHRM3, OPRD1 | TDP1 1899/4885L3MBTL1 4472/4885MEN1 4421/4885 |
| US-20150246026-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | NR4A1, CHRM4, NR4A3 | TDP1 4514/4885L3MBTL1 1655/4885MEN1 2925/4885 |
| US-10588895-B2 | Quinuclidine derivatives and medicinal compositions containing the same | CHRM3, QDPR, CHRM2 | TDP1 2705/4885L3MBTL1 4257/4885MEN1 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.